CPC C07K 16/2866 (2013.01) [A61K 39/39533 (2013.01); A61K 39/39541 (2013.01); A61K 39/39558 (2013.01); A61K 39/39566 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 14/55 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 15/85 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/20 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/32 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/40 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/60 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 2015/8518 (2013.01)] | 26 Claims |
1. An antibody or antigen-binding fragment thereof, comprising:
a) aCD25-a-672-HCDR3 amino acid sequence (SEQ ID NO: 4) as variable heavy chain complementarity determining region 3;
b) aCD25-a-672-HCDR1 amino acid sequence (SEQ ID NO: 2) as variable heavy chain complementarity determining region 1;
c) aCD25-a-672-HCDR2 amino acid sequence (SEQ ID NO: 3) as variable heavy chain complementarity determining region 2;
d) aCD25-a-672-LCDR1 amino acid sequence (SEQ ID NO: 6) as variable light chain complementarity determining region 1;
e) aCD25-a-672-LCDR2 amino acid sequence (SEQ ID NO: 7) as variable light chain complementarity determining region 2; and
f) aCD25-a-672-LCDR3 amino acid sequence (SEQ ID NO: 8) as variable light chain complementarity determining region 3.
|